The reimbursement environment is constantly changing. Requirements vary between markets and need coordination across multiple areas to produce high-quality results. To help you achieve market access, our experts across our health economics and market access and outcomes strategy teams have experience contributing to successful submissions in many countries and across therapeutic areas. Our integrated team approach can help you achieve the best result for your product.
We can support you in any aspects of research and product development you require for your reimbursement submissions.
Our experience includes:
- Strategic and technical support throughout the process, including early advice and post-submission support
- Writing the entire reimbursement submission or specific sections
- Developing all component parts of the reimbursement submission, or incorporating aspects developed elsewhere, including:
- Targeted review of burden of illness
- Systematic reviews of clinical literature
- Systematic reviews of utility, and economic literature
- Network and other meta analyses (Bayesian and frequentist methods)
- Utility research and resource use/cost estimation
- Cost effectiveness analyses
- Budget impact analyses
- Validation with payers
Our track record of successfully supporting submissions in major markets includes the following:
- Australia: PBAC
- Canada: CADTH, INESSS
- Denmark: DMC, Amgros, DMA
- Finland: Fimea, Hila
- Germany: AMNOG
- Norway: NoMa
- Republic of Ireland: NCPE
- Sweden: TLV
- United Kingdom: NICE, SMC, AWMSG
In addition to global HTA submissions, we routinely perform the full package of research underpinning AMCP dossiers and preparation for ICER engagements to support launches in the US.
